NHS England is to launch a trial of PrEP, a drug that dramatically reduces the risk of acquiring HIV. At least 10,000 people will be given the drug in a clinical trial lasting three years.
Simon Dowe, Chief Executive at The Sussex Beacon said, “The green light for this trial of PrEP is a great step forward in tackling HIV. We know it’s a very effective way to prevent HIV transmission and we hope this trial is a pre-cursor to rolling a PrEP programme out nationwide. Not only could this decision save lives, it’s also pragmatic financially. The cost of funding the drug would be far less than treating the HIV cases that PrEP could have prevented.”
To find out more about PrEP, click here: PrEP